薄荷油与薄荷糖治疗儿童肠易激综合征及功能性腹痛的随机试验
这项在荷兰13家医院开展的随机对照试验纳入228名8-18岁肠易激综合征或功能性腹痛患儿,比较双盲薄荷油胶囊、开放标签薄荷糖与双盲安慰剂。结果显示薄荷油和薄荷糖在8周治疗成功率及症状充分缓解方面均未优于安慰剂,不良事件轻微且少见。
要点
- 薄荷油胶囊与安慰剂相比,8周治疗成功率无显著差异(44.0% vs 37.3%)。
- 薄荷糖与安慰剂相比,症状充分缓解率亦无显著差异(44.9% vs 49.3%)。
- 不良事件轻微且少见,提示薄荷油在儿童中安全性可接受。
核心结论
- 薄荷油和薄荷糖在治疗儿童肠易激综合征及功能性腹痛方面均不优于安慰剂。
- 研究结果提示应优先选择针对脑-肠轴的已验证干预措施。
研究设计与样本
- 随机对照试验,在荷兰13家医院开展。
- 纳入228名8-18岁肠易激综合征或功能性腹痛患儿,按1:1:1随机分配。
- 干预组分别为双盲薄荷油胶囊(含182 mg薄荷油)、开放标签薄荷糖(9.2 mg薄荷油)和双盲安慰剂(2.0 mg薄荷油),每日2次(8-11岁)或3次(12-18岁),疗程8周,随访4周。
主要发现
- 不良事件轻微且少见。
关键数值与推荐
- 主要终点为治疗成功,定义为8周后腹痛强度较基线降低≥30%。
- 关键次要终点为症状充分缓解。
- 薄荷油胶囊剂量为182 mg,薄荷糖含9.2 mg薄荷油,安慰剂含2.0 mg薄荷油。
临床怎么用
- 不推荐将薄荷油或薄荷糖作为儿童肠易激综合征及功能性腹痛的常规治疗。
- 临床决策应优先考虑针对脑-肠轴的已有证据支持的干预措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Effective pharmacologic treatment for pediatric irritable bowel syndrome (IBS) and functional abdominal pain-not otherwise specified (FAP-NOS) is lacking. This study evaluated the efficacy and safety of peppermint oil, an antispasmodic agent, and peppermint sweets in children with IBS or FAP-NOS. METHODS: This randomized controlled trial was conducted across 13 Dutch hospitals. Participants (aged 8-18 years) with IBS or FAP-NOS were randomized (1:1:1) to double-blind peppermint oil capsules (containing 182 mg of peppermint oil), open-label peppermint sweets (9.2 mg peppermint oil), or double-blind placebo (2.0 mg peppermint oil to enhance blinding) twice daily (8-11 years) or 3 times daily (12-18 years), with dose escalation if needed. The intervention lasted 8 weeks with a 4-week follow-up. The primary endpoint was treatment success, defined as a ≥30% reduction of abdominal pain intensity after 8 weeks. The key secondary endpoint was adequate relief of symptoms. RESULTS: In 228 children (8-11 years: n = 92; 12-18 years: n = 135; 75-78 per group), treatment success was comparable between patients receiving peppermint oil (n = 30; 44.0%) and placebo (n = 28; 37.3%) (odds ratio [OR], 1.33; 97.5% confidence interval [CI], 0.58-3.09; P = .44), and between placebo and peppermint sweets (n = 30; 38.7%) (OR, 1.05; 97.5% CI, 0.45-2.44; P = .91). Adequate relief was comparable between treatment groups: peppermint oil (n = 40; 53.3%) vs placebo (n = 37; 49.3%) (OR, 1.15; 97.5% CI, 0.54-2.47; P = .68), and placebo vs peppermint sweets (n = 35; 44.9%) (OR, 0.81; 97.5% CI, 0.39-1.71; P = .53). Adverse events were mild and infrequent. CONCLUSIONS: Neither peppermint oil nor peppermint sweets were superior to placebo in treating pediatric IBS and FAP-NOS. These findings suggest prioritizing proven gut-brain axis-targeted interventions for this population. CLINICALTRIALS: gov, Number: NCT05799053.
引用
- Vermeijden NK, van der Feen C, Groeneweg M, et al. Peppermint Oil and Sweets in Pediatric Irritable Bowel Syndrome and Functional Abdominal Pain: A Randomized Trial. Clin Gastroenterol Hepatol. 2026. PMID: 41610933. doi:10.1016/j.cgh.2026.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。